Monte Rosa Therapeutics, Inc. (GLUE)
GLUENASDAQ-GSBiotechnology: Biological Products (No Diagnostic Substances)
$10.58
+0.0100 (+0.09%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $904.06m
- P/E
- –
- EPS, last 4 quarters
- $-1.40
- Dividend yield
- –
- Day range
- –
- 52-week range
- $9.68 to $25.77
- Average volume
- 1.36m
- Previous close
- $10.57
Analysts
9 coveringBuy9 buy, 0 hold, 0 sell
Targets a year out average $25.38, +139.9% from here
Earnings
next estimate $-0.1600Next report
Dec 2025
-17.0%
Mar 2026
-60.7%
Jun 2026
-72.0%
Sep 2026
+130.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $12.77m | $2.78m | $4.21m | $8.97m |
| Gross profit | $12.77m | $2.78m | $4.21m | $8.97m |
| Operating income | -$32.98m | -$49.72m | -$50.03m | -$49.13m |
| Net income | -$27.08m | -$46.13m | -$44.50m | -$43.40m |
Last four quarters: revenue $28.73m, margin -560.9%, free cash flow -$32.08m
News
8 latest- Monte Rosa Therapeutics Reports Third Quarter 2026 Financial ResultsFintel · 4 days ago
- Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue EstimatesZacks · 5 days ago
- Precigen, Inc. (PGEN) Q3 Earnings and Revenues Miss EstimatesZacks · 5 days ago
- Wall Street Analysts See a 152.87% Upside in Monte Rosa Therapeutics (GLUE): Can the Stock Really Move This High?Zacks · 7 days ago
- Monte Rosa Therapeutics (GLUE) May Report Negative Earnings: Know the Trend Ahead of Q3 ReleaseZacks · Oct 29, 2026
- Monte Rosa's MRT-6160 Enters Phase 2 Trial For Moderate To Severe Psoriatic Arthritis; Stock Up RTTNews · Oct 28, 2026
- Are Options Traders Betting on a Big Move in Monte Rosa Therapeutics Stock?Zacks · Oct 23, 2026
- Monte Rosa's MRT-8102 Shows Biomarker Gains in GFORCE-1 StudyMarketBeat · Oct 6, 2026
The company
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa's QuEEN (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry's leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- monterosatx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.